You searched for "dystrophy"
Ocular manifestations of Whipple’s disease
2 February 2024
| Lucy Osborne
|
EYE - Vitreo-Retinal
|
Granulomatous uveitis, Whipple’s disease, infectious uveitis, ocular infection, tropheryma whipplei
In this retrospective review of 217 patients with Whipple’s disease (WD), the authors reviewed the presentations of those with ocular manifestations. Ocular signs of WD are under recognised, frequently resulting in misdiagnosis and mismanagement. Mayo Data Explorer, a Mayo Clinic...
Results of fixed aflibercept treatment regime in type 3 neovascularisation
1 April 2020
| Sofia Rokerya
|
EYE - Vitreo-Retinal
In this prospective study the authors evaluate the effect of intravitreal aflibercept injections in the treatment of naive type 3 neovascularisation using a fixed treatment regime. Fourteen eyes of 14 patients were studied. All patients were treated with intravitreal 2.0...
Transient thickening of the macular retinal nerve fibre layer in acute optic neuritis
1 December 2022
| Claire Howard
|
EYE - Neuro-ophthalmology
|
Optic neuritis, axonal degeneration, neurofilament protein, retina, tissue
Acute optic neuritis (ON) causes axonal degeneration, which can be quantified from the blood by neurofilament protein (Nf) levels. Within about three months, atrophy of the retinal nerve fibre layer (RNFL) follows. However, it remains challenging to explain why there...
Contrast sensitivity in myopic eyes
3 June 2024
| Kurt Spiteri Cornish
|
EYE - Vitreo-Retinal
A classification system has been proposed for myopic maculopathy: grade 0 (no myopic retinal lesions), grade 1 (tessellated fundus), grade 2 (diffuse chorioretinal atrophy (CRA)), grade 3 (patchy CRA), and grade 4 (macular atrophy). Tessellated fundus is defined as the...
Could idebenone by the solution for treating dominant optic atrophy?
3 September 2024
| Claire Howard
|
EYE - Neuro-ophthalmology
Dominant optic atrophy (DOA) is a disease of the retinal ganglion cells, with no current treatment options. In most cases, DOA is caused by a mutation in the OPA1 gene. The aim of this study was to evaluate the effect...
Bosch-Boonstro-Schaaff optic atrophy syndrome (BBSOAS) NR2F1 mutation
4 December 2023
| Soman Raman, Neda Qurashi, Qasim Mansoor
|
EYE - Neuro-ophthalmology
An experienced ophthalmologist can make an anatomical diagnosis of childhood visual impairment based upon the surgical sieve, i.e., congenital and acquired. But an ophthalmologist cannot work in isolation to make an aetiological diagnosis – one would require the help of...
Nasolacrimal duct probing success
The aim of this study was to report the treatment effectiveness of primary probing in children with congenital nasolacrimal duct obstruction (CNLDO) and describe the factors relating to the failure of the procedure. This was a retrospective study of 62...Comparison of bupivacaine injection vs. mini-tenotomy for small angle deviations
Bupivacaine hydrochloride is an aminoacyltype local anaesthetic. Injection into extraocular muscles elicits a myotoxic response destroying striated muscle fibres but sparing satellite cells, nerves and vessels. Preserved satellite cells proliferate to form new muscle fibres, causing muscle hypertrophy and greater...What's trending Jun/Jul 2023
5 June 2023
| Liam YN Wong
|
EYE - General
A round-up of the eye-related hot topics that have been trending on social media over the last few weeks. #whoopigoldberg #presbyopia #bionic Whoopi Goldberg made a name for herself in blockbusters such as the Oscar-winning Ghost and Sister Act. She...
Risk factors and prognosis of paediatric open globe injuries
1 October 2021
| Sofia Rokerya
|
EYE - Vitreo-Retinal
|
Choroidal damage, Endophthalmitis, No light perception, Pediatric open globe injuries, Vitreoretinal surgery
This retrospective, comparative, interventional case-control study was aimed to investigate possible risk factors and prognosis of initial no light perception (NLP) in paediatric open globe injuries (POGI). A total of 851 cases were reviewed, including 837 unilateral cases and 14...
Emerging therapies for geographic atrophy: complement inhibitors show potential to slow progression and preserve RPE and photoreceptor integrity
5 June 2023
| Rod McNeil
Geographic atrophy (GA) is an advanced form of age-related macular degeneration (AMD) characterised by progressive, irreversible loss of the retinal pigment epithelium (RPE) and photoreceptors and is estimated to account for approximately 10% of AMD-related blindness [1-4]. The Age-Related Eye...
Update on emerging therapies for age-related macular degeneration
4 December 2023
| Rod McNeil
|
EYE - Vitreo-Retinal
The 23rd European Society of Retina Specialists (EURETINA) Congress, held in Amsterdam, the Netherlands, provided a timely update on anti-complement therapy for geographic atrophy and emerging investigational therapies for neovascular age-related macular degeneration. Anti-complement therapy for geographic atrophy Geographic atrophy...